Triggering tumor immunity through angiogenesis targeting

Same author

Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K <sup>+</sup> Supramolecular Attack Particles.

bioRxiv : the preprint server for biology·2026

Same author

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment: plain language summary of publication.

Therapeutic advances in gastroenterology·2026

Same author

Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.

Cancer cell·2026

Same author

Plasticity of tumor cell immunogenicity: is it druggable?

Journal for immunotherapy of cancer·2025

Same author

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan.

Journal of pharmaceutical health care and sciences·2025

Same journal

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Related Experiment Videos

Triggering tumor immunity through angiogenesis targeting

Related Concept Videos

Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K <sup>+</sup> Supramolecular Attack Particles.

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment: plain language summary of publication.

Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.

Plasticity of tumor cell immunogenicity: is it druggable?

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan.

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Related Experiment Videos

Triggering tumor immunity through angiogenesis targeting

Related Concept Videos

Related Articles

Human CD8-iTreg are potent GVHD suppressors and tumoricidal effectors by release of Granzyme-K <sup>+</sup> Supramolecular Attack Particles.

Biomarker analysis from patients with metastatic PDAC treated with TGFβ antibody, NIS793, plus abraxane+gemcitabine vs. abraxane+gemcitabine alone in a phase II, open label, randomized study.

Patient and physician preferences for treatment of hepatitis C virus infection in Japan: a discrete choice experiment: plain language summary of publication.

Identification of cycling regulatory T cell precursors as conductors of immune escape during breast carcinoma progression.

Plasticity of tumor cell immunogenicity: is it druggable?

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan.

Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.